Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2013

View Archived Issues

Ono obtains rights to opicapone for Parkinson's disease in Japan

Using microRNAs to differentiate between low- and high-risk pancreatic neoplasms

Roche develops interleukin-2 variant for cancer immunotherapy

Galapagos developing novel candidate drug for triple-negative breast cancer

Researchers discover novel genetic risk factor for Behcet's disease

Serum levels of beta-2-microglobulin predict mortality in patients with diabetes

New ways to protect from Parkinson's disease

SAR-154782 experiments reveal tumor growth pathways linked to NAMPT

Merck Serono obtains marketing rights to Cetrotide

Aurigene and Endo Pharmaceuticals achieve important milestones

FDA approves beta-blocker-free, fixed-combination therapy for glaucoma

Hexyon/Hexacima 6-in-1 pediatric vaccine approved in Europe

Indian scientists disclose novel CETP inhibitors

ViroPharma reports data from phase II study of VP-20621

GlaxoSmithKline presents new RORgamma modulators

MethylGene discovers novel VEGFR-2 inhibitors

Lundbeck describes new PDE10A inhibitors

Ono Pharmaceutical identifies novel S1P2 receptor antagonists

Aduro and Johns Hopkins University to evaluate Aduro vaccine technologies with anti-PD-1

ARCA biopharma and Medtronic to collaborate on atrial fibrillation burden substudy

Aastrom Biosciences commences treatment in phase IIb study of ixmyelocel-T

Synta begins treatment in confirmatory GALAXY-2 study of ganetespib

New agreement covers phase II HCV study of daclatasvir and MK-5172 combination

Senesco completes cohort 2 in phase Ib/IIa study of SNS01-T

Sareum and SRI International sign codevelopment agreement for TYK2 inhibitors

Interim phase II results for Mesoblast's mesenchymal precursor cells for intervertebral disc repair

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...